B18KA

General Information


DRACP ID  DRACP01015

Peptide Name   B18KA

Sequence  GFQKVKAQALTCLHTVMA

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MDA-MB-468 Breast adenocarcinoma Carcinoma IC50=135.6±9.3 µM MTT assay 24h 1
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=83.7±20.1 µM MTT assay 24h 1
ZR-75-1 Invasive breast carcinoma of no special type Carcinoma IC50=58.9±2.0 µM MTT assay 24h 1
T-47D Invasive breast carcinoma of no special type Carcinoma IC50=78.5±20.9 µM MTT assay 24h 1
SK-BR-3 Breast adenocarcinoma Carcinoma IC50=43.5±11.5 µM MTT assay 24h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=61.8±3.9 µM MTT assay 24h 1
MCF-7/G11-TR1 Breast cancer Carcinoma IC50=61.8±5.1 µM MTT assay 24h 1
MCF-7/G11-TR5 Breast cancer Carcinoma IC50=56.4±5.0 µM MTT assay 24h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  IC50 on PBMCs was = 92.0 ± 39.6 μM

Target  Not available

Affinity  Not available

Mechanism  may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/18 signaling and mitochondrial events.

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01015

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C86H144N24O23S2

Absent amino acids  DEINPRSWY

Common amino acids  A

Mass  224979

Pl  9.68

Basic residues  3

Acidic residues  0

Hydrophobic residues  8

Net charge  3

Boman Index  -108

Hydrophobicity  48.89

Aliphatic Index  92.22

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32872253

Title  Development of a Cationic Amphiphilic Helical Peptidomimetic (B18L) As A Novel Anti-Cancer Drug Lead

Doi 10.3390/cancers12092448

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.